stage II squamous cell carcinoma of the hypopharynx
Showing 1 - 25 of >10,000
Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Mucoepidermoid Carcinoma of the Oral Cavity, Recurrent Squamous
Recruiting
- Recurrent Adenoid Cystic Carcinoma of the Oral Cavity
- +50 more
- transoral robotic surgery
- quality of life assessment
-
Columbus, OhioOhio State University Medical Center
Oct 28, 2022
Squamous Cell Carcinoma of the Oral Cavity, Squamous Cell Carcinoma of the Larynx, Squamous Cell Carcinoma of the Hypopharynx
Not yet recruiting
- Squamous Cell Carcinoma of the Oral Cavity
- +3 more
- Eliminating RT to the elective neck
- RT standard of care
-
Erlangen, Bavaria, GermanyUniversitätsklinikum Erlangen, Strahlenklinik
Sep 8, 2023
Squamous Cell Carcinoma of Head and Neck, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma Stage III
Not yet recruiting
- Squamous Cell Carcinoma of Head and Neck
- +11 more
- KEYTRUDA®
- (no location specified)
Nov 17, 2023
Stage III, IVa, or IVb Squamous Cell Carcinoma of the Oral Cavity, Oropharynx, Larynx, or Hypopharynx Trial in Philadelphia
Active, not recruiting
- Stage III, IVa, or IVb Squamous Cell Carcinoma of the Oral Cavity, Oropharynx, Larynx, or Hypopharynx
- Nelfinavir (Viracept®) 1250 mg
- FMISO
-
Philadelphia, PennsylvaniaAbramson Cancer Center of the University of Pennsylvania
Jun 30, 2021
Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell
Completed
- Stage IV Squamous Cell Carcinoma of the Hypopharynx
- +3 more
-
Boston, Massachusetts
- +1 more
Feb 11, 2021
Esophageal Squamous Cell Carcinoma by AJCC V8 Stage Trial (Radiotherapy, Toripalimab)
Not yet recruiting
- Esophageal Squamous Cell Carcinoma by AJCC V8 Stage
- Radiotherapy
- Toripalimab
- (no location specified)
Mar 17, 2023
Esophageal Squamous Cell Carcinoma Trial in Wuhan (no intervention)
Recruiting
- Esophageal Squamous Cell Carcinoma
- no intervention
-
Wuhan, Hubei, ChinaRenmin hosptial of Wuhan University
Jul 29, 2023
Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck, Resectable Cutaneous Squamous Cell Carcinoma of the Head and
Recruiting
- Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck
- +4 more
- Cemiplimab
-
Houston, TexasM D Anderson Cancer Center
Jan 17, 2023
Squamous Cell Carcinoma of Head and Neck Trial in Houston (Control Group, TTI-101)
Not yet recruiting
- Squamous Cell Carcinoma of Head and Neck
- Control Group
- TTI-101
-
Houston, TexasM D Anderson Cancer Centerl
Apr 25, 2023
Neoadjuvent, PD-1 Inhibitor, Chemo Trial in Xi'an (Pembrolizumab, Albumin Paclitaxel, 5-fluorouracil, Cisplatin)
Recruiting
- Neoadjuvent
- +3 more
- Pembrolizumab, Albumin Paclitaxel, 5-fluorouracil, Cisplatin
-
Xi'an, Shaanxi, China
- +2 more
Aug 17, 2023
Squamous Cell Carcinoma of the Oropharynx, Squamous Cell Carcinoma of the Larynx, Squamous Cell Carcinoma of the Oral Cavity
Active, not recruiting
- Squamous Cell Carcinoma of the Oropharynx
- +7 more
-
Tampa, Florida
- +2 more
Dec 30, 2022
Metastatic Penile Squamous Cell Carcinoma, Stage III Penile Cancer AJCC v8, Stage IV Penile Cancer AJCC v8 Trial in Phoenix,
Not yet recruiting
- Metastatic Penile Squamous Cell Carcinoma
- +3 more
- Enfortumab Vedotin
-
Phoenix, Arizona
- +2 more
Oct 23, 2023
Head Neck Cancer, Metastatic Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma Trial in Winston-Salem (Pembrolizumab,
Recruiting
- Head Neck Cancer
- +5 more
- Pembrolizumab
- +2 more
-
Winston-Salem, North CarolinaWake Forest Baptist Health Sciences
Aug 8, 2022
Head and Neck Squamous Cell Carcinoma Trial in Dallas (Intensity modulated radiation therapy (IMRT))
Active, not recruiting
- Head and Neck Squamous Cell Carcinoma
- Intensity modulated radiation therapy (IMRT)
-
Dallas, TexasUniversity of Texas Southwestern Medical Center - Dallas
Nov 18, 2022
Stage T3 Squamous Cell Carcinomas of the Scalp
Active, not recruiting
- Squamous Cell Carcinoma
- +2 more
-
Maastricht, NetherlandsEllen Oyen
Aug 3, 2023
Advanced Esophageal Squamous Carcinoma With Oligometastases Trial (simultaneous with radiotherapy, synchronous with
Not yet recruiting
- Advanced Esophageal Squamous Carcinoma With Oligometastases
- simultaneous with radiotherapy
- synchronous with radiotherapy
- (no location specified)
Nov 16, 2023
Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive)
Recruiting
- Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
- +10 more
- Intensity-Modulated Radiation Therapy
- +4 more
-
Houston, TexasM D Anderson Cancer Center
Nov 8, 2022
Squamous Cell Carcinoma of the Skin Trial in Zhengzhou (Carrilizumab with albumin-binding paclitaxel)
Not yet recruiting
- Squamous Cell Carcinoma of the Skin
- Carrilizumab with albumin-binding paclitaxel
-
Zhengzhou, Henan, ChinaHenan Cancer Hospital
May 23, 2023
Oral Squamous Cell Carcinoma Trial in Beijing (Toripalimab)
Not yet recruiting
- Oral Squamous Cell Carcinoma
-
Beijing, ChinaPeking Union Medical College Hospital, Chinese Academy of Medica
Apr 5, 2023
Lung Squamous Cell Carcinoma Trial in Yancheng (To explore the efficacy and safety of immune checkpoint inhibitor combined with
Recruiting
- Lung Squamous Cell Carcinoma
- To explore the efficacy and safety of immune checkpoint inhibitor combined with endostar and chemotherapy in the treatment of advanced lung squamous cell carcinoma (stage IIIB-IV).
-
Yancheng, Jiangsu, ChinaYancheng Clinical College of Xuzhou Medical University
Mar 21, 2023
Head and Neck Squamous Cell Carcinoma, HNSCC, Squamous Cell Carcinoma of the Larynx Trial (Cemiplimab-Rwlc)
Withdrawn
- Head and Neck Squamous Cell Carcinoma
- +4 more
- (no location specified)
Aug 1, 2022
Oropharynx Squamous Cell Carcinoma, Larynx Squamous Cell Carcinoma, Hypopharynx Squamous Cell Carcinoma Trial in Brussels
Recruiting
- Oropharynx Squamous Cell Carcinoma
- +3 more
- IO102
- IO103
-
Brussels, BelgiumCliniques Universitaires Saint-Luc
May 6, 2022
Head and Neck Squamous Cell Carcinoma, Radiotherapy, Radiosensitizer Trial in China (Pirfenidone, Placebo)
Recruiting
- Head and Neck Squamous Cell Carcinoma
- +3 more
- Pirfenidone
- Placebo
-
Guangzhou, Guangdong, China
- +4 more
Nov 16, 2023
Esophageal Squamous Cell Carcinoma Trial in Shanghai (Sintilimab, Chemotherapy)
Not yet recruiting
- Esophageal Squamous Cell Carcinoma
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Nov 30, 2023
Hend and Neck Squamous Cell Carcinoma Locally Advanced Operable Trial in Guangzhou (Cetuximab, Zimberelimab, Docetaxel)
Not yet recruiting
- Hend and Neck Squamous Cell Carcinoma Locally Advanced Operable
- Cetuximab
- +3 more
-
Guangzhou, Guangdong, ChinaSun Yat-sen University
Oct 24, 2023